Crizotinib Patent Expiration
Crizotinib is used for treating ALK-positive inflammatory myofibroblastic tumors, metastatic non-small cell lung cancer, and relapsed or refractory systemic anaplastic large cell lymphoma in pediatric and young adult patients over 1 year of age. It was first introduced by Pf Prism Cv
Crizotinib Patents
Given below is the list of patents protecting Crizotinib, along with the drug name that holds that patent and the company name owning that drug.
| Drug Used in | Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Drug Owner |
|---|---|---|---|---|
| Xalkori | US8217057 | Polymorphs of a c-MET/HGFR inhibitor | Nov 06, 2029 | Pf Prism Cv |
| Xalkori | US7858643 | Enantiomerically pure aminoheteroaryl compounds as protein kinase inhibitors | Oct 08, 2029 | Pf Prism Cv |
| Xalkori | US7825137 | Method of treating abnormal cell growth | May 12, 2027 | Pf Prism Cv |
| Xalkori | US7230098 | Aminoheteroaryl compounds as protein kinase inhibitors |
Aug 26, 2025
(Expired) | Pf Prism Cv |
| Xalkori | US8785632 | Enantiomerically pure aminoheteroaryl compounds as protein kinase inhibitors |
Mar 01, 2025
(Expired) | Pf Prism Cv |
A patent's expiry date may change depending upon legal activities going on that patent. Critical
activities like
abandoning of a patent, term extension of a patent or amendment of its claims can increase or
decrease the life of a
patent hence affecting its expiry date and in turn affecting the generic launch date of that
drug. Tracking these
ongoing activities on a patent application helps to keep an eye on the latest developments in
the patent process of
the drug which can give an idea of how early a drug's generic could be available. The next
section provides a list
of recent legal activities on Crizotinib's patents.
Latest Legal Activities on Crizotinib's Patents
Given below is the list recent legal activities going on the following patents of Crizotinib.
| Activity | Date | Patent Number |
|---|---|---|
 | ||
| Maintenance Fee Reminder Mailed | 09 Mar, 2026 | US8785632 |
| Payment of Maintenance Fee, 12th Year, Large Entity | 14 Dec, 2023 | US8217057 |
| Payment of Maintenance Fee, 12th Year, Large Entity | 11 May, 2022 | US7858643 |
| Payment of Maintenance Fee, 12th Year, Large Entity | 12 Apr, 2022 | US7825137 |
| Payment of Maintenance Fee, 8th Year, Large Entity | 09 Dec, 2021 | US8785632 |
| Payment of Maintenance Fee, 8th Year, Large Entity | 18 Dec, 2019 | US8217057 |
| Payment of Maintenance Fee, 12th Year, Large Entity | 15 Nov, 2018 | US7230098 |
| Payment of Maintenance Fee, 8th Year, Large Entity | 09 May, 2018 | US7858643 |
| Payment of Maintenance Fee, 8th Year, Large Entity | 13 Apr, 2018 | US7825137 |
| Payment of Maintenance Fee, 4th Year, Large Entity | 15 Dec, 2017 | US8785632 |
Crizotinib's Family Patents
Explore Our Curated Drug Screens
Clinical Trials
Recent Clinical Trials on Crizotinib:
Sometimes companies keep conducting clinical trials even after the drug's approval to discover new formulations, methods of use, or new treatment indications, so they could file for additional patents or receive regulatory exclusivity extensions, such as pediatric exclusivity, potentially delaying generic competition. Based on these recent clinical trials, generic companies need to consider the potential for new intellectual property or regulatory hurdles. These strategic moves by the drug owner might delay generic substitution or lead to additional sales of the brand drug, even after patent expiry.
